Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Carlo Marani, MD, Raffaella Grasso, PhD, Nicoletta Colombo, Marino Clavio, MD, Fabio Guolo, MD, Annalisa Kunkl, Livia Giannoni, MD, Giuseppina Fugazza, PhD, Roberto Bruzzone, Mario Sessarego, MD, A. M. Carella, MD, Marco Gobbi, MD, Maurizio Miglino, PhD

Blood (2012) 120 (21): 2535.

https://doi.org/10.1182/blood.V120.21.2535.2535

Published: 2012

Journal Articles

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

Blood (2011) 117 (25): 6793–6800.

https://doi.org/10.1182/blood-2011-01-328294

Published: 2011

Includes: Supplemental data

Journal Articles

Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker

Blood (2009) 114 (14): 3127–3130.

https://doi.org/10.1182/blood-2008-12-190991

Published: 2009

Journal Articles

The Persistence of p190 BCR-ABL Transcripts Is Associated with Lower Probability of Molecular Response to Imatinib in Early and Late Chronic Phase CML Patients.

Anna Garuti, PhD, Adalberto Ibatici, MD, Gabriella Cirmena, PhD, Maurizio Miglino, MD, Riccardo Varaldo, MD, Colombo Nicoletta, PhD, Roberta Grasso, PhD, Sarah Pozzi, PhD, Marina Podesta, PhD, Marco Gobbi, MD, Mario Sessarego, MD, Franco Patrone, MD, Francesco Frassoni, MD

Blood (2005) 106 (11): 3282.

https://doi.org/10.1182/blood.V106.11.3282.3282

Published: 2005

Journal Articles

Molecular Responders (<3-log Reduction) among CML Patients in Complete Cytogenetic Remission Show a Lower Number of BCR-ABL+ Hematopoietic Progenitors Compared to Non-Responders.

Adalberto Ibatici, Giusy Fugazza, Nadia Sessarego, Marina Podesta, Stefania Agliano, Sarah Pozzi, Mirko Corselli, Anna Garuti, Mario Sessarego, Francesco Frassoni

Blood (2005) 106 (11): 4325.

https://doi.org/10.1182/blood.V106.11.4325.4325

Published: 2005

Journal Articles

Autografting With Philadelphia Chromosome–Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia

Angelo M. Carella, Enrica Lerma, Maria T. Corsetti, Anna Dejana, Palmina Basta, Franca Vassallo, Monica Abate, Monica Soracco, Federica Benvenuto, Osvaldo Figari, Marina Podestà, Giovanna Piaggio, Raimondo Ferrara, Mario Sessarego, Caterina Parodi, Michele Pizzuti, Alessandra Rubagotti, Domenico Occhini, Francesco Frassoni

Blood (1999) 93 (5): 1534–1539.

https://doi.org/10.1182/blood.V93.5.1534

Published: 1999

Journal Articles

The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia

Marina Podestà, Giovanna Piaggio, Francesco Frassoni, Anna Pitto, Panagiotis Zikos, Mario Sessarego, Monica Abate, Maria Teresa Van Lint, Giovanni Berisso, Andrea Bacigalupo

Blood (1998) 91 (6): 1959–1965.

https://doi.org/10.1182/blood.V91.6.1959

Published: 1998

NARROW

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker

The Persistence of p190 BCR-ABL Transcripts Is Associated with Lower Probability of Molecular Response to Imatinib in Early and Late Chronic Phase CML Patients.

Molecular Responders (<3-log Reduction) among CML Patients in Complete Cytogenetic Remission Show a Lower Number of BCR-ABL+ Hematopoietic Progenitors Compared to Non-Responders.

Autografting With Philadelphia Chromosome–Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia

The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker

The Persistence of p190 BCR-ABL Transcripts Is Associated with Lower Probability of Molecular Response to Imatinib in Early and Late Chronic Phase CML Patients.

Molecular Responders (<3-log Reduction) among CML Patients in Complete Cytogenetic Remission Show a Lower Number of BCR-ABL+ Hematopoietic Progenitors Compared to Non-Responders.

Autografting With Philadelphia Chromosome–Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia

The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only